Bal Pharma Limited — Board Meeting, 13-02-2025: Outcome of Board Meeting

The Board of Directors of Bal Pharma Limited has met and approved the unaudited standalone and consolidated financial results for the quarter ending December 31, 2024. The consolidated revenue from operations is ₹73.69 crore, with a total income of ₹73.66 crore. Profit before tax stands at ₹9.66 crore, while the net profit for the period is ₹8.79 crore. The board also decided to defer consideration of fundraising options due to unfavorable market conditions. A copy of the approved financial results is attached for reference.